SQI Diagnostics - CEO, Andrew Morris
CEO, Andrew Morris
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • SQI Diagnostics Inc. (SQD) has installed its Rapid Acute Lung Injury Diagnostic (RALI-Dx) IL-6 Severity Triage Test at two hospitals in Toronto
  • The test will be used in the emergency departments (EDs) and as part of a study to help fight the growing respiratory health crisis
  • RALI-Dx helps to identify which adult patients are most at risk of a severe inflammatory response and worst patient outcomes
  • The intended use of the test is the screening of patients at elevated risk of intubation with mechanical ventilation
  • SQI Diagnostics Inc. (SQD) is unchanged, trading at $0.12 per share as of 2:58 p.m. EST

SQI Diagnostics Inc. (SQD) has installed its Rapid Acute Lung Injury Diagnostic (RALI-Dx) IL-6 Severity Triage Test at two University Health Network (UHN) hospitals in Toronto

The test will be used in the hospital’s emergency departments (EDs) and as part of a study to help fight the growing respiratory health crisis in those departments.

Andrew Morris, President and CEO of SQI Diagnostics, commented,

“We believe a respiratory triage test will be a vital tool enabling physicians to manage the ongoing respiratory health crisis in our EDs.”

The test was initially developed to clarify COVID-19 patients’ risk. By testing for the presence of the biomarker Il-6, RALI-Dx helps to identify which adult patients are most at risk of a severe inflammatory response and worst patient outcomes. The intended use of the test is the screening of higher-risk patients with mechanical ventilation.

The test was designed by physicians at UHN and was licensed and further developed by SQI Diagnostics. The company conducted clinical studies globally to assess RALI-Dx performance in a real-world emergency department setting. The observed negative predictive value in the test study was 88.70 per cent.

Dr. Shaf Keshavjee, Medical Director and Chief of Innovation at UHN added,

“There is currently no suitable diagnostic that can guide clinicians to rapidly assess the severity of a patient’s respiratory inflammation and subsequent triage to the appropriate care.”

SQI Diagnostics Inc. (SQD) is unchanged, trading at $0.12 per share as of 2:58 p.m. EST.


More From The Market Herald

" Osisko Metals (TSXV:OM) invites investors to join them at the Vancouver Resource Investment Conference

Osisko Metals (OM) invites investors to attend the Vancouver Resource Investment Conference (VRIC).

" Plurilock (TSXV:PLUR) appoints Blake Corbet to its Board of Directors

The duo-listed cybersecurity solutions provider, Plurilock Security (PLUR), appoints Blake Corbet to its Board of Directors.

" Current Water Technologies (TSXV:WATR) signs agreement with Singapore-based Separtis Technologies Global

Current Water Technologies (WATR) has established a binding memorandum of agreement with Separtis Technologies Global Pte Ltd of Singapore.

" St Charles Resources (TSXV:SCRS.P) signs new agreement for qualifying transaction with Eastern Resources OOD

St Charles Resources (SCRS.P) has signed a business combination agreement with Eastern Resources OOD Eastern Resources.